Clinical Trial Results:
Immune Response to Influenza Vaccine in Subjects with B-cell Malignancies Treated with Idelalisib
Summary
|
|
EudraCT number |
2017-003055-30 |
Trial protocol |
FR GB CZ PL ES |
Global end of trial date |
09 Oct 2019
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
07 Aug 2020
|
First version publication date |
07 Aug 2020
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
GS-US-313-4100
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT03701438 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Gilead Sciences
|
||
Sponsor organisation address |
333 Lakeside Drive, Foster City, CA, United States, 94404
|
||
Public contact |
Gilead Clinical Study Information Center, Gilead Sciences, GileadClinicalTrials@gilead.com
|
||
Scientific contact |
Gilead Clinical Study Information Center, Gilead Sciences, GileadClinicalTrials@gilead.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
09 Oct 2019
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
09 Oct 2019
|
||
Was the trial ended prematurely? |
Yes
|
||
General information about the trial
|
|||
Main objective of the trial |
The primary objective of this study was to assess the immune response to an influenza vaccine in adults with B-cell malignancies who were receiving treatment with idelalisib in a Gilead-sponsored study (parent study: GS-US-313-1580 [NCT02536300]).
|
||
Protection of trial subjects |
The protocol and consent/assent forms were submitted by each investigator to a duly constituted Independent Ethics Committee (IEC) or Institutional Review Board (IRB) for review and approval before study initiation. All revisions to the consent/assent forms (if applicable) after initial IEC/IRB approval were submitted by the investigator to the IEC/IRB for review and approval before implementation in accordance with regulatory requirements.
This study was conducted in accordance with recognized international scientific and ethical standards, including but not limited to the International Conference on Harmonization guideline for Good Clinical Practice (ICH GCP) and the original principles embodied in the Declaration of Helsinki.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
23 Oct 2018
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Spain: 1
|
||
Country: Number of subjects enrolled |
Czech Republic: 1
|
||
Worldwide total number of subjects |
2
|
||
EEA total number of subjects |
2
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
1
|
||
From 65 to 84 years |
1
|
||
85 years and over |
0
|
|
|||||||
Recruitment
|
|||||||
Recruitment details |
Participants were enrolled at study sites in Europe. The first participant was screened on 23 October 2018. | ||||||
Pre-assignment
|
|||||||
Screening details |
2 participants were screened. | ||||||
Period 1
|
|||||||
Period 1 title |
Overall Study (overall period)
|
||||||
Is this the baseline period? |
Yes | ||||||
Allocation method |
Not applicable
|
||||||
Blinding used |
Not blinded | ||||||
Arms
|
|||||||
Arm title
|
Idelalisib/Influenza Vaccine | ||||||
Arm description |
Participants who were receiving treatment with idelalisib (100 mg or 150 mg tablets orally twice daily) for at least 7 consecutive days prior to receiving an influenza vaccine in a Gilead-sponsored parent study (GS-US-313-1580 [NCT02536300]), continued to receive idelalisib (per dose and schedule of parent study) along with the influenza vaccine within 7 days of baseline (Day 1) blood sample collection, administered per standard of care using a vaccine licensed and recommended in the site’s country. | ||||||
Arm type |
Experimental | ||||||
Investigational medicinal product name |
Influenza Vaccine
|
||||||
Investigational medicinal product code |
|||||||
Other name |
|||||||
Pharmaceutical forms |
Solution for injection
|
||||||
Routes of administration |
Subcutaneous use
|
||||||
Dosage and administration details |
Administered per standard of care using a vaccine licensed and recommended in the site's country.
|
||||||
Investigational medicinal product name |
Idelalisib
|
||||||
Investigational medicinal product code |
|||||||
Other name |
|||||||
Pharmaceutical forms |
Tablet
|
||||||
Routes of administration |
Oral use
|
||||||
Dosage and administration details |
Administered per dose and schedule of parent study.
|
||||||
|
|
|||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||
Reporting group title |
Idelalisib/Influenza Vaccine
|
||||||||||||||||||||||||||||||
Reporting group description |
Participants who were receiving treatment with idelalisib (100 mg or 150 mg tablets orally twice daily) for at least 7 consecutive days prior to receiving an influenza vaccine in a Gilead-sponsored parent study (GS-US-313-1580 [NCT02536300]), continued to receive idelalisib (per dose and schedule of parent study) along with the influenza vaccine within 7 days of baseline (Day 1) blood sample collection, administered per standard of care using a vaccine licensed and recommended in the site’s country. | ||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Idelalisib/Influenza Vaccine
|
||
Reporting group description |
Participants who were receiving treatment with idelalisib (100 mg or 150 mg tablets orally twice daily) for at least 7 consecutive days prior to receiving an influenza vaccine in a Gilead-sponsored parent study (GS-US-313-1580 [NCT02536300]), continued to receive idelalisib (per dose and schedule of parent study) along with the influenza vaccine within 7 days of baseline (Day 1) blood sample collection, administered per standard of care using a vaccine licensed and recommended in the site’s country. |
|
|||||||||
End point title |
Seroconversion Rate: Percentage of Participants with Either a Pre-Vaccination Hemagglutination Inhibition (HI) Titer < 1:10 and a Post-Vaccination HI titer ≥ 1:40, or a Pre-Vaccination HI titer ≥ 1:10 and a ≥ 4-fold Increase in Post-Vaccination HI Titer [1] | ||||||||
End point description |
|||||||||
End point type |
Primary
|
||||||||
End point timeframe |
28 days (± 7 days) post-vaccination
|
||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Due to early termination of study, no efficacy analyses were performed. |
|||||||||
|
|||||||||
Notes [2] - Due to early termination of study, no efficacy analyses were performed. |
|||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Seroprotection Rate: Percentage of Participants with HI titer ≥ 1:40 Post-Vaccination | ||||||||
End point description |
|||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
28 days (± 7 days) post-vaccination
|
||||||||
|
|||||||||
Notes [3] - Due to early termination of study, no efficacy analyses were performed. |
|||||||||
No statistical analyses for this end point |
|
|||||||||
End point title |
Geometric Mean Titers (GMTs) of Antibodies: Pre- and Post-Vaccination GMTs of HI Antibodies | ||||||||
End point description |
|||||||||
End point type |
Secondary
|
||||||||
End point timeframe |
Pre-vaccination and 28 days (± 7 days) post-vaccination
|
||||||||
|
|||||||||
Notes [4] - Due to early termination of study, no efficacy analyses were performed. |
|||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Percentage of Participants with Adverse Events or Serious Adverse Events | ||||||||||||
End point description |
All Enrolled Analysis Set included all participants who enrolled into the study after screening and had a subject identification number.
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Date of Informed consent up to Day 28 (post-vaccination visit)
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Date of Informed consent up to Day 28 (post-vaccination visit)
|
||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
All Enrolled Analysis Set included all participants who enrolled into the study after screening and had a subject identification number.
|
||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
22.1
|
||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Idelalisib/Influenza Vaccine
|
||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Participants who were receiving treatment with idelalisib (100 mg or 150 mg tablets orally twice daily) for at least 7 consecutive days prior to receiving an influenza vaccine in a Gilead-sponsored parent study (GS-US-313-1580 [NCT02536300]), continued to receive idelalisib (per dose and schedule of parent study) along with the influenza vaccine within 7 days of baseline (Day 1) blood sample collection, administered per standard of care using a vaccine licensed and recommended in the site’s country. | ||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||
|
|
|||||||
Substantial protocol amendments (globally) |
|||||||
Were there any global substantial amendments to the protocol? Yes | |||||||
Date |
Amendment |
||||||
31 Jan 2018 |
Based on responses from site selection and feasibility discussions, the protocol was revised to allow participants to receive an influenza vaccination per
Standard of Care (SoC) in an inpatient or outpatient medical setting, including but not necessarily limited to hospitals, clinics, health departments, and general
practitioner offices. In addition, revisions were made to improve the operational feasibility of the study. |
||||||
12 Apr 2018 |
Following submission of the clinical trial application via the Voluntary Harmonization Procedure (VHP), Gilead received requests to amend the study from the participating member states in VHP. This protocol amendment addressed the VHP’s requests. |
||||||
Interruptions (globally) |
|||||||
Were there any global interruptions to the trial? Yes | |||||||
|
|||||||
Limitations and caveats |
|||||||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||||||
The study was terminated early and only 2 participants were enrolled so no efficacy analyses and no summary analyses were conducted. |